加巴喷丁联合α-硫辛酸治疗糖尿病痛性神经病变的疗效观察被引量：3

Effect of Alpha Lipoic Acid and Gabapentin for Diabetic Painful Neuropathy

下载PDF

导出

摘要目的观察加巴喷丁联合α-硫辛酸对糖尿病痛性神经病变的疗效及其对炎性因子的影响。方法 98例糖尿病痛性神经病变患者随机分为3组:常规组、α-硫辛酸组和综合组,3组患者均给予常规治疗,α-硫辛酸组加用α-硫辛酸治疗,综合组采用加巴喷丁联合α-硫辛酸治疗。分别于治疗前和治疗3周后检测神经传导速度、血清超敏C反应蛋白(hypersensitive c-reactive protein,hs-CRP)、肿瘤坏死因子(tumor necrosis factor-α,TNF-α)和白细胞介素-6(interleukin-6,IL-6),同时观察记录治疗前后疼痛强度变化,进行疗效评价。结果治疗3周后,综合组总有效率明显高于α-硫辛酸组和常规组(P<0.01)。3组患者神经传导速度均有升高、血清炎性因子均较前降低,差异均有统计学意义(P<0.05)。α-硫辛酸组和综合组治疗后上述指标和常规组比较差异有统计学意义(P<0.05)。结论α-硫辛酸联合加巴喷丁治疗可有效改善糖尿病痛性神经病变。 Objective To observe the effect of alpha lipoic acid and gabapentin for diabetic painful neuropathy and its effects on inflammatory factors. Method 98 diabetic neuropathy patients were at random divided into 3 groups： routine group, alpha lipoic acid group and combination group. They were all given conventional treatment. Alpha lipoic acid group were treated with alpha lipoic acid, and combination group were given the gabapentin combination with alpha lipoic acid. We observed the changes of nerve conduction velocity, hs-CRP, TNF-α, IL-6 and the effect evaluation of DNP before and after treatment. Results The total efficacy rate in the combination group was significant better than that in routine group and alpha lipoic acid group（P〈 0.01）; There is a significant Improvement of nerve conduction velocity and a decrease of inflammatory factors in three groups after three weeks treatment（P0.05）. Conclusion Gabapentin combined with alpha lipoic acid could be an effective therapy for diabetic painful neuropathy.

作者李群于凤泉

机构地区山东省临沂市沂水中心医院内分泌科

出处《中国医药指南》 2015年第18期22-24,共3页 Guide of China Medicine

关键词 Α-硫辛酸加巴喷丁糖尿病痛性神经病变炎性因子 Alpha lipoic acid Gabapentin Diabetic painful neuropathy Inflammatory factors

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献11

1Rowbotham M,Harden N,Stacey B,et al.Gabapentin for the treatment of posttherpetic neuralgia,a randomized controlled trial[J].JAMA,1998,280(21):1837-1842.
2Feldman EL.Oxidative stress and diabetic neuropathy:a new underStanding of an old problem[J].J Clin Invest,2003,111(4):431-433.
3Valensia P,Le Devehatb C,Richard J,et al.A multicenter,doubleblind,safety study of symptomatic diabetic peripheral neuropathy a preliminary report[J].J Diabetes Complicat,2005,19(10):247-253.
4Palacka P,Kucharska J,Murin J,et al..Complementary therapy in diabetic patients with chronic complications:a pilot study[J].Bratial Lek Listy,2010,111(4):205-211.
5黄海,祝开思,王平,曲建昌,季雪飞,宋梅.α-硫辛酸联合前列腺素E_1治疗糖尿病性周围神经病变疗效观察[J].中国临床保健杂志,2008,11(1):29-30. 被引量：17
6侯宁宁,邱明才.糖尿病神经病变中的免疫机制[J].国际内分泌代谢杂志,2007,27(1):68-69. 被引量：10
7Drel V,Lupachyk S,Shevalye H,et al.New therapeutic and biomarker Discovery for peripheral diabetic neuropathy:PARP inhibitor,nitrotyrosine and tumor necrosisfactor[J].Endorcrinology,2010,151(6):2547-2555.
8Said G,Lacmix C,Lozeron P,et al.Infammatory vasculopathy in multifocal diabetic neuropathy[J].Brain,2003,126(2):376-385.
9姜宏卫,滕中杰,马瑜瑾,李利平,付留俊,刘婕,宋白利.α-硫辛酸与甲钴胺联合治疗糖尿病周围神经病变[J].中国医药,2009,4(3):183-184. 被引量：12
10Chong MS,Hester J.Diabetic painful neuropathy:current and future treatment opitions[J].Drugs,2007,67(12):1795-1807.

二级参考文献14

1[1]Feldman EL.Oxidative stress and diabetic neuropathy:a new understanding of an old problem[J].J Clin Invest,2003,111 (4):431-433.
2[2]Greene DA,Sima AAF,Stevens MJ,et al.Alodose reductase inhibitors:an approach to the treatment of diabetic nerve damage[J].Diabetes Metab Rev,1993,9 (3):189-217.
3[4]Kanamau K,Waga S,Kuga Y,et al.Transcranial Doppler Pattern after intracarotid Papaverine and prostaglandin E1 incorporated inlipid microsphere in patients with vasospasm[J].Neurol Med Chir (Tokyo),1998,38 Suppl:152.
4[5]Ziegler D,Nowak H,Kempler P,et al.Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:a meta-analysis[J].Diabet Med,2004,21(2):114-121.
5Misur I,Zarkovic K,Barada A,et al.Advanced glycation end products in peripheral nerve in type 2 diabetes with neuropathy.Acta Diabetol,2004,41:158-166.
6Towns R,Kabeya Y,Yoshimori T,et al.Sera from patients with type 2 diabetes and neuropathy induce autophagy and colocalization with mitochondria in SY5Y cells.Autophagy,2005,1:163-170.
7Sinnreich M,Taylor BV,Dyck PJ.Diabetic Neuropathies Classification,clinical features,and pathophysiological basis.Neurologist,2005,11:63-79.
8Said G,Lacroix C,Lozeron P,et al.Infammatory vasculopathy in multifocal diabetic neuropathy.Brain,2003,126:376-385.
9Fernandes-Filho JA,Nathan BM,Palmert MR,et al.Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin.Muscle Nerve,2005,32:818-820.
10Dyck P,Norell JE,Dyck PJ.Non-diabetic lumbosacral radiouloplexus neuropathy:natural history,outcome and comparison with the diabetic variety.Brain,2001,124:1197-1207.